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Background: Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD). Endothelial
progenitor cell (EPCs) dysfunction plays a key role in this pathogenesis. Uremic retention toxins have been reported
to be in associated with EPC dysfunction. Advanced glycation end-products (AGEs) free adducts, including
Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-(carboxyethyl)lysine (CEL), are formed by physiological
proteolysis of AGEs and released into plasma for urinary excretion. They are retained in CKD patients and are
considered to be potential uremic toxins. Though AGEs have been demonstrated to impair EPC function in various
ways, the effect of AGE free adducts on EPC function has not been studied. Thus, we examined the role of CML
and CEL in the regulation of growth-factor-dependent function in cultured human EPCs and the mechanisms by
which they may affect EPC function.
Methods: Late outgrowth EPCs were incubated with different concentrations of CML or CEL for up to 72 hours.
Cell proliferation was determined using WST-1 and BrdU assays. Cell apoptosis was tested with annexin V staining.
Migration and tube formation assays were used to evaluate EPC function.
Results: Though CML and CEL were determined to have anti-proliferative effects on EPCs, cells treated with
concentrations of CML and CEL in the range found in CKD patients had no observable impairment on migration or
tube formation. CML and CEL did not induce EPC apoptosis. The reduced growth response was accompanied by
significantly less phosphorylation of mitogen-activated protein kinases (MAPKs).
Conclusions: Our study revealed that CML and CEL at uremic concentrations have low biological toxicity when
separately tested. The biologic effects of AGE free adducts on the cardiovascular system merit further study.
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Patients with chronic kidney disease (CKD) are at high
risk of cardiovascular disease (CVD) [1,2]. Endothelial
dysfunction plays a key role in this pathogenesis [3-5].
Recent studies have repeatedly shown that decreased
numbers of endothelial progenitor cells (EPCs), as in the
case of CKD patients, is associated with an increase in
the number of cardiovascular events [6-9]. The factors
that cause such EPC-linked pathology in CKD patients
are still not well understood.
CKD is attributed to the progressive retention of a
large number of compounds which, under normal condi-
tions, are excreted by the healthy kidneys [10]. These
compounds are called uremic retention solutes, or when
they interact negatively with biological functions, uremic
toxins. Protein-bound uremic toxins constitute a hetero-
geneous group of compounds which are difficult to be
removed by dialysis [11]. Inadequate removal of protein-
bound uremic toxins has been reported as a primary
cause of CVD in CKD patients [12,13]. Several protein-
bound uremic toxins have been associated with EPC
dysfunction [14,15].
Advanced glycation end-products (AGEs) are the re-
sult of a chain of chemical reactions after an initial gly-
cation reaction. AGEs were evaluated in CKD patients
and considered as candidate protein-bound uremic tox-
ins [16,17]. The negative impact of AGEs on EPCs has
been demonstrated repeatedly [18-21]. Physiological pro-
teolysis of AGEs forms protein glycation free adducts
that are released into the plasma for urinary excretion.
Inefficient elimination of these free adducts in uremia
may lead to their accumulation [22,23]. Patients with
mild chronic renal failure not requiring dialysis had
plasma glycation free adduct concentrations increased
up to five-fold the normal level, associated with a decline
in renal clearance. Patients on peritoneal dialysis (PD)
had plasma glycation free adducts levels up to 18 times
higher than normal, and those treated with hemodialysis
(HD) up to 40 times higher [23].
Nepsilon-(carboxymethyl)lysine (CML) and Nepsilon-
(carboxyethyl)lysine (CEL) are two main glycation free
adducts in CKD patients. The European Uremic Toxin
(EUTox) Work Group defined CML as protein-bound
uremic toxins and CEL as potential toxins to be consid-
ered in the future [17,24]. Clinical studies have found a
correlation between CML levels and mortality in
hemodialysis patients [25]. CML has been associated
with increased aortic pulse wave velocity in adults [26].
Animal studies show CML accelerates atherosclerotic
calcification in diabetes [27]. In vitro studies show CML-
albumin and CEL-albumin stimulate VCAM-1 expres-
sion in endothelial cells and activates leukocyte
responses [28,29]. For these reasons, we decided to in-
vestigate the effects of CML and CEL on EPC function.In the present study, we hypothesized that CML and
CEL might have a deleterious impact on EPC function.
We investigated the role of CML and CEL in the regula-
tion of growth-factor-dependent function among cul-
tured human EPCs and the mechanisms by which they
might affect EPC function.
Materials and methods
This study was approved by the Institutional Review
Board of Shanghai Jiaotong University School of
Medicine.
Reagents
CML and CEL were purchased from Santa Cruz Co.
(CA, USA). They were dissolved in 0.9% sodium chloride
to a final concentration of 1 mg/ml and served as stock-
ing solutions. Endotoxin levels of CML and CEL were
measured by end-point quantitative chromogenic assay
using the Tachypleus Amebocyte Lysate kit (Houshiji,
Xiamen, China). The final preparation of these two com-
pounds contained undetectable levels of endotoxin
(detection sensitivity of 1 EU/μg).
Culture and determination of human late outgrowth EPCs
Culture and determination of human late outgrowth
EPCs were performed as previously reported [30].
Mononuclear cells (MNCs) were isolated from 20 ml
human peripheral blood by Ficoll density-gradient cen-
trifugation (1.077 g/ml Sigma, MO, USA). Recovered
MNCs were then washed twice with phosphate buffered
saline (PBS) and resuspended with Medium 199 (Gibco,
MI, US) supplemented with 10% fetal bovine serum
(FBS) and EGM-2 Single Quotes (Lonza, MD, USA).
Cells were seeded on human fibronectin-coated (BD
Biosciences, CA, USA) six-well plates and incubated in a
5% CO2 incubator at 37°C. Late EPCs colonies appeared
after 2–4 weeks of culture. These cells were harvested
and cultured for later experiments. Evaluations revealed
cellular incorporation of acetylated LDL and UEA-1
binding affinity. Fluorescence-activated cell sorting
(FACS) analysis showed that these cells were CD34-posi-
tive, CD31-positive, VEGFR2-positive, CD45-negative,
and CD133-negative.
EPC proliferation assays
The effects of CML and CEL alone on EPC proliferation
were determined using two methods: (i) WST-1 assay kit
(Roche Applied Science, Mannheim, Germany) and (ii)
BrdU Labeling and Detection Kit (Calbiochem, NJ,
USA). For the WST-1 assay, 5,000 cells per well were
seeded in 96-well culture plates and incubated for 24
hours. CML at mean concentrations of 15, 46, 137, 412,
1235, 3704, 11111, 33333, and 100000 μg/L and CEL at
mean concentrations of 46, 137, 412, 1235, 3704, 11111,
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ture plates and incubated for 48 and 72 hours in a 5%
CO2 incubator at 37°C. Sodium chloride solution served
as a control. Ten microliters of cell proliferation assay
reagent WST-1 was added to each well and incubated
for 4 hours. Absorbance of 450 nm was measured by an
enzyme linked immunosorbent assay (ELISA) reader
(BioTek, VT, USA). For the BrdU assay, cells were incu-
bated with BrdU and different concentrations of CML or
CEL for 24 hours. Cellular incorporation of BrdU was
measured by ELISA with a BrdU Labeling and Detection
Kit, according to the manufacturer’s instructions.Tube formation assay
The tube formation capacity of EPCs was investigated
using matrigel, as previously described [31]. Concen-
trations of CML and CEL similar to those found in
CKD patients [25] were chosen to study. EPCs were
incubated with 250, 500, and 1000 μg/L of CML or
CEL for 72 hours. Controls received the same volume
of sodium chloride solution. EPCs (2 × 104 cells per
well) were harvested and placed on a 96-well glass
slide pre-coated with Matrigel (BD Bioscience, CA,
USA). After 12 hours of incubation, six random high-
power (100x) microscope fields were examined and
graded by two investigators as follows: 0, separated
individual cells; 1, cells begin to migrate and align; 2,
capillary tubes visible, but no sprouting; 3, sprouting
of new capillary tubes visible; 4, closed polygons
begin to form; and 5, complex mesh-like structures
develop. The average of these six fields was taken.
Investigators were blinded to experiment protocol.EPC migration assay
The migratory function of EPCs was evaluated using a
modified Boyden chamber (Transwell, Corning Inc.,
MA, USA) assay. In brief, EPCs were incubated using
different concentrations of CML or CEL as described in
the tube formation assay for 72 hours. EPCs (4 × 104
cells per well) were then harvested, resuspended in 0.5%
FBS, and placed in the upper chamber of 24-well trans-
well plates with a polycarbonate membrane (8 μm
pores). VEGF (50 ng/ml) in medium was added to the
lower chamber. After incubation for 12 hours, the mem-
brane was washed briefly with hank’s balanced salt solu-
tion (HBSS). The upper side of the membrane was
wiped gently with cotton wool. The membrane was then
stained using Hochest 33342 (Invitrogen, CA, USA). Mi-
gration of EPCs was evaluated by measuring the area
containing migrated cells as a percentage of the total
area. Six random high-power (100x) microscope fields
were examined and the average of these six fields was
taken. The experiment was repeated three times.Cell apoptosis assay
The effect of CML or CEL on EPC apoptosis was deter-
mined with an Annexin V-Alexa Fluor 488 kit (Invitrogen,
OR, USA). EPCs cultured on 6-well culture plates were
treated with different concentrations of CML or CEL, as
described in the tube formation assay. After 72 hours, cells
were detached with trypsin, washed in M199 medium
containing 10% FBS, centrifuged, and washed with ice-
cold PBS. After centrifugation, the pellets were resus-
pended in binding buffer containing Alexa Fluor 488-
annexin V and propidium iodide, mixed gently, and incu-
bated on ice for 10 minutes in the dark. The samples were
read using a FACSCalibur flow cytometer (Becton–Dick-
inson, CA, USA) at 494 nm. A 520 nm bandpass filter was
used for Alexa Fluor 488 detection, and a greater than
600 nm filter was used for propidium iodide detection.
The percentage of annexin-V-positive cells in the EPC
population was determined using CellQuest Pro software
(Becton–Dickinson, CA, USA). The experiment was
repeated three times.
Preparation of cell lysates and Western blotting
After EPCs were exposed to different concentrations of
CML or CEL in complete medium 199 for up to 72 hours,
they were rinsed twice with ice-cold PBS. Protein was
extracted using ProteoJET Mammalian Cell Lysis Reagent
(Fermentas, MD, USA). The protein content of cell lysates
was separated on 10 or 12% gels using SDS-PAGE, and
transferred to a PVDF membrane. Membranes were incu-
bated overnight with the primary antibodies in Tris Buf-
fered Saline with Tween-20 (TBST) and 5% bovine serum
albumin (BSA) at 4°C. The membranes were washed three
times with TBST and incubated for 1 hour at room
temperature in horseradish peroxidase-conjugated goat
anti-mouse or goat anti-rabbit secondary antibodies
(1:7500 dilution in TBST containing 5% nonfat milk). The
immunoreactive proteins were detected using an ECL
Western blotting detection system (Millipore, MA, USA).
Detection of GAPDH was used as the protein loading con-
trol. Each experiment was repeated three times. A repre-
sentative blot is shown for each experiment.
Statistical analysis
Data were analyzed using SPSS 13.0 software (SPSS, Inc.
Chicago, USA). Results were expressed as mean± stand-
ard deviation (SD). Statistically significant differences
among different treatment groups at a single point in
time were determined by non-parametric tests. Statis-
tical significance was assumed for p<0.05.
Results
Effects of CML and CEL on EPC proliferation
The effects of CML or CEL alone on EPC proliferation
were first analyzed by WST-1 assay. Incubation of EPCs
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72 hours both induced significant reductions in the
number of adherent EPCs. This inhibition was dose-
dependent (Figure 1A, B). The WST-1 results were con-
firmed by ELISA analyzing BrdU incorporation into cel-
lular DNA, which showed CML and CEL inhibited EPC
proliferation in a dose-dependently manner after 24
hours of incubation (Figure 1C, D).
Effects of CML and CEL on EPC tube formation, migration,
and apoptosis
CML or CEL alone at mean concentrations of 250, 500,
and 1000 μg/L were chosen for studies of their effects
on EPC tube formation, migration, and apoptosis. We
first used a Matrigel model to examine whether CML or
CEL alone would decrease EPCs ability to differentiate
into capillary-like structures. Compared with control
groups, CML and CEL had no observable effects on
EPC tube formation. To determine the effects of CML
or CEL alone on EPC migration, we counted cells mov-
ing through an insert filter in a chamber filled with
medium 199 and 0.5% FBS. CML and CEL did not de-
crease EPC migration compared to the control group.
The decreased numbers of EPCs after ex vivo incubation
of CML or CEL may be the result of several factors. Pre-
vious studies demonstrated that AGEs could induce EPC
apoptosis [19]. Thus, we determined whether CML or
CEL could also induce EPC apoptosis using annexin V-Figure 1 Effects of CML and CEL on EPC proliferation. (A+B) EPCs wer
counted after 48 and 72 hours using the WST-1 method. (C+D) BrdU inco
CEL for 24 hours were measured using enzyme-linked immunosorbent assa
experiments. *p<0.05 vs control, #p<0.01 vs. control.FACS staining. Incubation of EPCs with different con-
centrations of CML or CEL for 72 hours did not induce
cell apoptosis (Figure 2).
Effects of CML and CEL on RAGE expression in EPCs
After observing the anti-proliferative effects of CML and
CEL alone on EPCs, we next evaluated the expression of
Receptor for advanced glycation end products (RAGE) in
cells. RAGE is the main receptor through which AGE sig-
naling is mediated [32]. In these experiments, EPCs were
first incubated with different concentrations of CML or
CEL for 72 hours. No CML and CEL-induced difference in
RAGE expression was observed in EPCs. To further investi-
gate the expression of RAGE protein in EPCs, cells were
then incubated with 500 μg/L CML or CEL for 0, 24, 48,
and 72 hours. CML and CEL did not increase RAGE pro-
tein expression in EPCs either (Figure 3).
Effects of CML and CEL on MAPK activity
The mitogen-activated protein kinases (MAPKs) and AKT
signaling pathways have been shown to be involved in cel-
lular proliferation. For these reasons, we investigated the
activities of MAPK and AKT in EPCs treated with CML or
CEL. Incubation of EPCs with CML or CEL for 24 hours
down-regulated MAPK activity in a dose-dependent man-
ner. The activity of ERK1/2, JNK1, and p38 MAPK were
similarly down regulated in a dose-dependent manner.
Treatment did not inhibit AKTactivity (Figure 4).e incubated with different concentrations of CML or CEL alone and
rporation into EPCs incubated with different concentrations of CML or
y (ELISA). Data were expressed as mean± SD of five independent
Figure 2 Effects of CML and CEL on EPC tube formation, migration, and apoptosis. EPCs were incubated with 250, 500, or 1000 μg/L of
CML, CEL, or control for 72 hours and then tested. (A) Typical cell tube formation, migration, and apoptosis (100x). (B) Bar graph. No significant
differences were observed between any of the different groups. Data were expressed as mean± SD of three independent experiments.
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In the past ten years, the understanding of endothelial
dysfunction in CKD has greatly expanded. Important
findings include the discovery of circulating EPC, reflect-
ing endothelial repair capacity, and the demonstration ofFigure 3 Regulation of RAGE expressions in EPCs incubated with diffe
concentration-dependent experiment, EPCs were incubated with 250, 500,
dependent experiment, EPCs were incubated with 500 μg/L of CML or CEL
to western blot analysis. (B) Bar graph. No CML or CEL-induced difference i
mean± SD of three independent experiments.the specific toxicity of uremic compounds [13]. The rela-
tionship between circulating EPC levels and uremic tox-
ins in CKD patients is not well understood [15].
AGEs have been identified in the blood and tissues of
patients with ESRD [33]. Oxidative and carbonyl stress haverent concentrations of CML/CEL for different times. (A) In the
or 1000 μg/L of CML, CEL, or control for 72 hours. In the time-
for 0, 24, 48, or 72 hours. Aliquots of cell lysate were then subjected
n RAGE expression was observed in EPCs. Results were expressed as
Figure 4 Effects of CML and CEL on the MAPK and AKT signaling pathways in EPCs. (A) After incubation of EPCs with different
concentrations of CML or CEL for 24 hours, aliquots of cell lysate were subjected to western blot analysis. (B) The quantities of phosphorylated
and total kinases were estimated using Quantity One software. CML and CEL inhibited phosphorylation of MAPKs, including ERK1/2, JNK1, and
p38 MAPK, in a dose-dependent manner, but did not inhibit AKT. Similar results were obtained in three separate experiments. Data were
expressed as mean± SD. *p<0.05 vs. control, #p<0.01 vs. control.
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undergo cellular proteolysis and are released into plasma as
AGE free adducts for urinary excretion [35]. These glyca-
tion free adducts include free fructoselysine (FL), free
hydroimidazolones, CML, CEL, pentosidine, and other
AGEs [35]. The normal high renal clearance of AGE free
adducts is impaired markedly in CKD and thus considered
as potential uremic toxins [17].
AGEs have been demonstrated to impair endothelial
functions in several ways. They up-regulate adhesion mol-
ecule expression [36] and increase endothelial layer perme-
ability [37]. In vitro, AGEs prompt intracellular generation
of hydrogen peroxide and activation of nicotinamide aden-
ine dinucleotide phosphate (NADPH) oxidase [38]. AGEs
enhance apoptosis, depress EPC migration and tube forma-
tion in a concentration-dependent manner, and increase
RAGE expression in these cells [18-20]. The negative im-
pact of AGEs on bone marrow mesenchymal stem cells
(MSCs) has been reported by us previously [39].
Mixtures of AGEs have been prepared for study after a
long, complex, in vitro preparation process, resulting in
“AGE-modified” proteins of unknown composition [40].
Few studies have used the complete range of genuine
uremic AGE compounds. Glorieux et al. [29] reported
that genuine AGE compounds, including CML and CEL,
could activate leukocyte response and hence play a rolein uremia related atherogenesis. Wang et al. [27] found
that CML could accelerate progression of atherosclerotic
calcification in diabetes. In the present study, the bio-
logic effects of CML and CEL were studied, with specific
emphasis on EPC function.
We believe the concentrations of CML and CEL used
in this study requires special comment. EUTox reported
the maximum concentration of CML is 6.9 mg/L in
CKD patients in 2003 [19]. In their follow-up publica-
tion in 2007 [41], EUTox reported the maximum con-
centration (Cmax) of CML to be 111–221 nM ( 40 μg/
L) and CEL to be 336–817 nM ( 200 μg/L) in CKD
patients [23]. Recently, EUTox reported the Cmax of
CML as 18.5 mg/L in CKD patients [24]. These different
concentrations of CML and CEL might be explained by
their use of different analytical methods, ELISA [17,24]
and liquid chromatography-mass spectrometry (LC-MS)
[41]. The quantification of AGEs using ELISA is prob-
lematic. Because of uncertain epitope specificity of anti-
bodies employed, and the use of highly modified
standard antigens dissimilar to the minimally modified
antigens in physiological samples, AGE detection using
ELISA does not usually provide AGE levels in absolute
concentration, but rather in arbitrary units with or with-
out normalisation to a reference AGE protein standard
[42]. LC-MS analysis is now becoming the standard
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believe the findings published in 2007 were correct,
according to our previous analysis (mean serum concen-
tration of CML in ESRD patients without dialysis
therapy 200 μg/L using LC-MS analysis, n = 5, data not
published). For this reason we used CML and CEL in
the 250–1000 μg/L range in this study. We believe previ-
ously published concentrations (2003, 2012) were higher
than our study because of their use of ELISA to detect
AGE.
MAPKs are a family of serine/threonine kinases
comprised of extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinase (JNK), and p38
MAPK (p38) [43]. Growth factor-induced proliferation
of EPC has been demonstrated to be regulated by ac-
tivation of the MAPK signaling pathway [44,45]. The
MAPK signaling pathway activation has been demon-
strated to be biphasic [46-50], with an early rapid in-
crease in MAPK activation from 5 to 60 minutes,
followed by a late second wave of MAPK activation
of lower amplitude beginning at 7–10 hours. This
second wave of MAPK activity was sustained for
hours after growth factor stimulation and was critical
for cellular progression from G1 into S phase
[46,48,49,51]. In this study, the activity of MAPKs in
EPCs treated with CML or CEL for 24 hours was
tested. The reduced growth response to CML or CEL
in EPCs was accompanied by significantly less phos-
phorylation of MAPKs, suggesting that CML and CEL
may reduce EPCs proliferation via inhibition of the
MAPK signaling pathway.
Our study found that CML and CEL had no effects on
AGE receptor (RAGE) expressions in EPCs. This is con-
sistent with previous studies, which found that CML-
modified proteins were unable to bind to RAGE [52].
This may be because proteins modified by AGEs to a
high extent (30–40 AGE residues per molecule) are
competent AGE receptor ligands, whereas proteins
modified by AGEs to a minimal extent (1–2 AGE resi-
dues per molecule) are not [53,54].
Limitations
Though our results indicate that CML and CEL in
uremic concentrations were less toxic on EPC functions,
we did not study them together. The mechanism of tox-
icity of both CML and CEL will be the source of further
study. Their in vivo effect on EPC function, like postna-
tal neovascularization, should also be studied.
We found that the anti-proliferative effects of CML
and CEL on EPCs were associated with down-regulation
of MAPK phosphorylation. Whether this could mediate
inhibition of EPCs is still unknown. Signaling pathway
inhibition experiments could be performed to confirm
this hypothesis.Conclusions
It has not yet been determined which of the individual
AGE uremic compounds exert toxic biologic effects [55].
In the present study, the effect of chemically well-
defined AGE compounds, CML and CEL, on EPC func-
tions was evaluated. Our study revealed that CML and
CEL have low biological toxicity when separately tested.
The biologic effects of AGE free adducts on the cardio-
vascular system merits further study.
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